A detailed history of Vanguard Group Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 6,206,814 shares of SUPN stock, worth $168 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,206,814
Previous 6,214,731 0.13%
Holding current value
$168 Million
Previous $180 Million 17.71%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$27.11 - $35.17 $214,629 - $278,440
-7,917 Reduced 0.13%
6,206,814 $212 Million
Q4 2023

Feb 14, 2024

BUY
$22.72 - $29.68 $3.24 Million - $4.23 Million
142,551 Added 2.35%
6,214,731 $180 Million
Q3 2023

Nov 14, 2023

BUY
$27.57 - $32.91 $791,562 - $944,879
28,711 Added 0.48%
6,072,180 $167 Million
Q2 2023

Aug 14, 2023

BUY
$29.91 - $38.73 $4.86 Million - $6.29 Million
162,404 Added 2.76%
6,043,469 $182 Million
Q1 2023

May 15, 2023

BUY
$34.93 - $42.03 $3.18 Million - $3.83 Million
91,105 Added 1.57%
5,881,065 $213 Million
Q4 2022

Feb 10, 2023

BUY
$31.09 - $37.88 $3.41 Million - $4.16 Million
109,718 Added 1.93%
5,789,960 $207 Million
Q3 2022

Nov 14, 2022

BUY
$28.79 - $35.41 $1.72 Million - $2.12 Million
59,794 Added 1.06%
5,680,242 $192 Million
Q2 2022

Aug 12, 2022

BUY
$25.33 - $34.25 $2.07 Million - $2.8 Million
81,628 Added 1.47%
5,620,448 $163 Million
Q1 2022

May 13, 2022

BUY
$28.51 - $32.9 $731,880 - $844,575
25,671 Added 0.47%
5,538,820 $179 Million
Q4 2021

Feb 14, 2022

BUY
$26.37 - $34.22 $933,656 - $1.21 Million
35,406 Added 0.65%
5,513,149 $161 Million
Q3 2021

Nov 12, 2021

SELL
$23.54 - $31.39 $157,270 - $209,716
-6,681 Reduced 0.12%
5,477,743 $146 Million
Q2 2021

Aug 13, 2021

BUY
$26.72 - $33.19 $147 Million - $182 Million
5,484,424 New
5,484,424 $169 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.45B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.